Revised SPC: Ranexa (ranolazine) prolonged-release Tablets- all strengths

Myoclonus has been added to SPC as an adverse event of unknown frequency. The SPC has also been updated to advise that in postmarketing experience, there have been reports of intentional overdose of ranolazine alone or in combination with other drugs with a fatal outcome.

electronic Medicines compendium